Ilaria Zanotti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8474600/publications.pdf

Version: 2024-02-01

40	2,157	293460	325983
papers	citations	24 h-index	40 g-index

41	41	41	3772
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159065.	1.2	5
2	Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications. Journal of Clinical Medicine, 2021, 10, 2233.	1.0	15
3	Impact of Dietary Lipids on the Reverse Cholesterol Transport: What We Learned from Animal Studies. Nutrients, 2021, 13, 2643.	1.7	14
4	Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis. Atherosclerosis Plus, 2021, 44, 18-18.	0.3	1
5	Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 254-264.	1.1	9
6	Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232095924.	1.1	10
7	Ephrin or not? Six tough questions on Eph targeting. Expert Opinion on Therapeutic Targets, 2020, 24, 403-415.	1.5	10
8	Three-Dimensional (3D) Printed Silver Nanoparticles/Alginate/Nanocrystalline Cellulose Hydrogels: Study of the Antimicrobial and Cytotoxicity Efficacy. Nanomaterials, 2020, 10, 844.	1.9	34
9	Lipid trafficking in cardiovascular disease. Advances in Clinical Chemistry, 2019, 92, 105-140.	1.8	10
10	Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis. International Journal of Molecular Sciences, 2019, 20, 351.	1.8	177
11	HDL-Targeted Therapies During Myocardial Infarction. Cardiovascular Drugs and Therapy, 2019, 33, 371-381.	1.3	14
12	Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians. Journal of Lipid Research, 2018, 59, 714-721.	2.0	21
13	Alcohol Pattern Consumption Differently Affects the Efficiency of Macrophage Reverse Cholesterol Transport in Vivo. Nutrients, 2018, 10, 1885.	1.7	3
14	Anti-Atherosclerotic Effect of a Polyphenol-Rich Ingredient, OleactivÂ®, in a Hypercholesterolemia-Induced Golden Syrian Hamster Model. Nutrients, 2018, 10, 1511.	1.7	4
15	Phenyl-Î³-valerolactones, flavan-3-ol colonic metabolites, protect brown adipocytes from oxidative stress without affecting their differentiation or function. Molecular Nutrition and Food Research, 2017, 61, 1700074.	1.5	31
16	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017, 256, 1-6.	0.4	98
17	Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Proteinâ€“Protein Interaction Inhibitors Targeting the EphA2 Receptor. Journal of Medicinal Chemistry, 2017, 60, 787-796.	2.9	32
18	Targeting Eph/ephrin system in cancer therapy. European Journal of Medicinal Chemistry, 2017, 142, 152-162.	2.6	80

#	Article	IF	Citations
19	The Gut Microbial Metabolite Trimethylamine-N-Oxide Is Present in Human Cerebrospinal Fluid. Nutrients, 2017, 9, 1053.	1.7	108
20	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 315-320.	1.2	47
21	Antiatherogenic effects of ellagic acid and urolithins inÂvitro. Archives of Biochemistry and Biophysics, 2016, 599, 42-50.	1.4	59
22	Evidence for cholesterol-lowering activity by Bifidobacterium bifidum PRL2010 through gut microbiota modulation. Applied Microbiology and Biotechnology, 2015, 99, 6813-6829.	1.7	64
23	Cholesterol Efflux and Reverse Cholesterol Transport. Handbook of Experimental Pharmacology, 2015, 224, 181-206.	0.9	109
24	Î”5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€“ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324.	2.6	38
25	Atheroprotective effects of (poly)phenols: a focus on cell cholesterol metabolism. Food and Function, 2015, 6, 13-31.	2.1	126
26	Therapeutic perspectives of Ephâ€“ephrin system modulation. Drug Discovery Today, 2014, 19, 661-669.	3.2	38
27	Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EPHA2â€“ephrin-A1 Interaction. Journal of Chemical Information and Modeling, 2014, 54, 2621-2626.	2.5	13
28	Distant Homology Modeling of LCAT and Its Validation through In Silico Targeting and In Vitro and In Vivo Assays. PLoS ONE, 2014, 9, e95044.	1.1	6
29	Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion. PLoS ONE, 2013, 8, e71572.	1.1	6
30	Cellular Cholesterol Efflux Pathways: Impact on Intracellular Lipid Trafficking and Methodological Considerations. Current Pharmaceutical Biotechnology, 2012, 13, 292-302.	0.9	42
31	Macrophage, But Not Systemic, Apolipoprotein E Is Necessary for Macrophage Reverse Cholesterol Transport In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 74-80.	1.1	60
32	The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. Journal of Lipid Research, 2008, 49, 954-960.	2.0	54
33	A Unique Protease-sensitive High Density Lipoprotein Particle Containing the Apolipoprotein A-IMilano Dimer Effectively Promotes ATP-binding Cassette A1-mediated Cell Cholesterol Efflux. Journal of Biological Chemistry, 2007, 282, 5125-5132.	1.6	68
34	Relative Contributions of ABCA1 and SR-BI to Cholesterol Efflux to Serum From Fibroblasts and Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 541-547.	1.1	98
35	Pitavastatin Effect on ATP Binding Cassette A1-Mediated Lipid Efflux from Macrophages: Evidence for Liver X Receptor (LXR)-Dependent and LXR-Independent Mechanisms of Activation by cAMP. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 395-401.	1.3	29
36	Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages. FEBS Letters, 2005, 579, 6537-6542.	1.3	22

#	Article	IF	Citations
37	Probucol Inhibits ABCA1-Mediated Cellular Lipid Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2345-2350.	1.1	139
38	Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochemical and Biophysical Research Communications, 2004, 321, 670-674.	1.0	31
39	Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene. Journal of Lipid Research, 2003, 44, 254-264.	2.0	29
40	Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo. Circulation, 2003, 108, 661-663.	1.6	403